Onkologie. 2018:12(1):7-11 | DOI: 10.36290/xon.2018.002

The role of FDG PET/CT in the management of malignant melanoma

David Zogala
Ústav nukleární medicíny Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy v Praze

Positron emission tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) is a well established method in oncological practice.Malignant melanoma (MM) typically belongs to the tumours with high FDG-avidity. The highest impact of FDG PET/CT in the diagnosisof MM is in the primary staging and restaging of advanced stages (AJCC III-IV). FDG PET/CT can be used in the case of clinicallysuspected disease relapse. The evidence level is currently insufficient to define the exact value of FDG PET/CT in the therapy effectassessment (mainly for novel therapeutic modalities as immunotherapy and kinase inhibition). Limited number of research studiesshow that FDG PET/CT could have prognostic impact in this setting. It can be useful in the evaluation of systemic metastases ofnon-cutaneous MM. Conversely FDG PET/CT seems to have low value in the primary staging of early stage cutaneous MM (AJCC I-II).Unspecific nature of FDG and the tendency to produce false positive findings must be kept in mind in clinical practice.

Keywords: malignant melanoma, PET, CT, FDG

Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zogala D. The role of FDG PET/CT in the management of malignant melanoma. Onkologie. 2018;12(1):7-11. doi: 10.36290/xon.2018.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42: 328-354. Go to original source... Go to PubMed...
    2. Věstník Ministerstva zdravotnictví ČR, č. 2/2016, Národní radiologické standardy - Nukleární medicína: 314-319.
    3. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011; 103(2): 129-142. Go to original source... Go to PubMed...
    4. Wagner T, Chevreau C, Meyer N, et al. Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol. 2012; 26(11): 1431-1435. Go to original source... Go to PubMed...
    5. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006; 141(3): 284-288. Go to original source... Go to PubMed...
    6. McIvor J, Siew T, Campbell A, et al. FDG PET in early stage cutaneous malignant melanoma. J Med Imaging Radiat Oncol. 2014; 58(2): 149-154. Go to original source... Go to PubMed...
    7. Ortega-Candil A, Rodríguez-Rey C, Cano-Carrizal R, et al. Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established? Rev Esp Med Nucl Imagen Mol. 2016; 35(2): 96-101. Go to original source... Go to PubMed...
    8. Rodriguez Rivera AM, Alabbas H, et al. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol. 2014; 23(1): 11-16. Go to original source... Go to PubMed...
    9. National Comprehensive Caner Network: Clinical Practice Guidelines in Oncology [online]. USA. [cit. 11-1-2018]. Dostupné z https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf
    10. Schüle SC, Eigentler TK, Garbe C, et al. Influence of (18) F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging. 2016; 43(3): 482-488. Go to original source... Go to PubMed...
    11. Forschner A, Olthof SC, Gückel B, et al. Impact of (18)F-FDG PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging. 2017; 44(8): 1312-1318. Go to original source... Go to PubMed...
    12. Stodell M, Thompson JF, Emmett L, et al. Melanoma patient imaging in the era of effective systemic therapies. Eur J Surg Oncol. 2017; 43(8): 1517-1527. Go to original source... Go to PubMed...
    13. Koskivuo I, Kemppainen J, Giordano S, et al. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma. Acta Oncol. 2016; 55(11): 1355-1359. Go to original source... Go to PubMed...
    14. Kurtz J, Beasley GM, Agnese D, et al. Surveillance strategies in the follow-up of melanoma patients: too much or not enough? J Surg Res. 2017; 214: 32-37. Go to original source... Go to PubMed...
    15. Leon-Ferre RA, Kottschade LA, Block MS, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017; 27(4): 335-341. Go to original source... Go to PubMed...
    16. Wong ANM, McArthur GA, Hofman MS, et al. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1): 67-77. Go to original source... Go to PubMed...
    17. McArthur GA, Puzanov I, Amaravadi R, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012; 30(14): 1628-1634. Go to original source... Go to PubMed...
    18. Sachpekidis C, Larribere L, Pan L, et al. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015; 42(3): 386-396. Go to original source... Go to PubMed...
    19. Kong BY, Menzies AM, Saunders CA, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016; 29(5): 572-527. Go to original source... Go to PubMed...
    20. Murphy G, Hussey D, Metser U. Non-cutaneous melanoma: is there a role for (18)F-FDG PET-CT? Br J Radiol. 2014; 87(1040): 20140324. Go to original source... Go to PubMed...
    21. Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, et al. Extracutaneous melanomas: a primer for the radiologist. Insights Imaging. 2015; 6(6): 707-717. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.